PJ analysis: online pharmacy weight loss prescribing safety

May 2026. The Royal Pharmaceutical Society's own journal published a deep-dive on what's going wrong with remote weight-loss prescribing. It runs 17 minutes' reading and cites 27 references — from GPhC guidance to a study on detecting altered patient images in online consultations.

CheckMyClinic has tracked every GPhC review and MHRA action on weight-loss medicines since 2023. This PJ analysis is the clinical evidence backbone that explains why the regulators are acting.

Here's what you need to know.

What the PJ analysis says

The article frames obesity as a chronic, relapsing disease affecting 30% of adults in England, with a further 66% overweight. The clinical case for GLP-1 medicines is strong. The question is whether the remote prescribing safeguards are keeping up.

The analysis flags three specific patient safety risks:

Inadequate pre-screening. The PJ cites research showing inconsistent application of remote prescribing principles — including failure to verify weight and BMI independently, inadequate eating disorder screening, and insufficient patient history checks before initiating GLP-1 therapy.

Image manipulation in online consultations. The journal references its own 2026 study on detecting altered images in online GLP-1 consultations. This is a real operational risk: patients submitting fabricated weight records or photos to bypass prescribing safeguards.

Weak ongoing monitoring. The analysis highlights gaps in follow-up care after initiation — patients starting GLP-1 medicines remotely without clear pathways for adverse event reporting, dose adjustments, or treatment review.

How this connects to the GPhC review

These aren't theoretical risks. The GPhC's own review of weight-management pharmacy inspections (April 2026) found exactly these patterns in real inspections: weak risk assessments, incomplete patient records, and inconsistent BMI verification.

We covered the GPhC findings separately — read the full analysis here. The short version: inspectors found that too many online pharmacies are cutting corners on safeguards for weight-loss medicines, and the GPhC has made clear that enforcement is coming.

The PJ analysis gives the clinical context the GPhC review needs. When a regulator says "risk assessments are weak," the clinical literature shows what good risk assessment looks like: independent BMI verification, eating disorder screening using validated tools like the SCOFF questionnaire, and documented remote prescribing protocols.

These two publications — the clinical analysis and the regulatory review — point in the same direction. Safeguards need to tighten, and the evidence base for what "good" looks like is already established.

What this means for clinics and pharmacies

Your pre-screening processes will face scrutiny. If you're prescribing GLP-1 medicines through online consultations, expect inspectors to check whether you independently verify weight and BMI rather than relying on patient-submitted data.

Image verification is becoming a compliance issue. The PJ's own research on detecting altered images signals that this is on the radar. If you're not already checking for manipulated consultation photos, you will be expected to.

Ongoing monitoring is not optional. Starting a patient on semaglutide or tirzepatide remotely is only the first step. The GPhC standards require documented follow-up, adverse event monitoring, and clear review protocols. The PJ analysis confirms what good looks like.

And the timing matters more than you might think. Just days ago (3 July 2026), the MHRA approved Wegovy for MASH liver disease — expanding semaglutide's indications and broadening the addressable patient population for private prescribing. More patients means more scrutiny.

What to watch next

The GPhC has said it will continue working with the MHRA and ASA on joint enforcement of weight-loss medicine prescribing. The PJ analysis gives the clinical foundation for that enforcement.

Expect targeted inspections of pharmacies prescribing GLP-1 medicines remotely — and potentially the first enforcement actions against providers that fail to meet the strengthened safeguards outlined in both the GPhC review and the clinical literature.

We're tracking this. As the regulator responds and new research emerges, CheckMyClinic will continue to monitor the regulatory landscape for UK clinic prescribing.